| SciPort RLP

2023 - 2040

A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with topotecan for the treatment of patients with small cell lung cancer (DAREONTM-9) (#1508)

Dr. Jürgen

2023 - 2040

An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors (INSIGHT) (#1493)

Dr. Jürgen

2023 - 2040

Venetoclax in combination with the BTK inhibitor Ibrutinib and rituximab or conventional chemotherapy (bendamustine) and ibrutinib and rituximab in patients with treatment naïve Mantle Cell Lymphoma not eligible for high dose therapy - The European Mantle Cell Lymphoma Elderly III-Trial (#1281)

Univ.-Prof. Dr. Georg

2023 - 2040

A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (#1417)

Dr. Marius

2023 - 2026

Characterization of age-related functional alterations in healthy T cells that are essential for efficient CAR T cell products

Dr. Astrid

2023 - 2026

Modifying macrophage polarization to improve cancer immunotherapies

Dr. Astrid,
Dr. Toszka

2023 - 2030

CARMAN/BIO CARMAN

Univ.-Prof. Dr. Georg

2023 - 2025

Projekt modulare Aufklärung

Dr. Stephanie

2023 - 2030

TRILONG/Multiply

Univ.-Prof. Dr. Georg

2023

EMCL RWE Tecartus

Univ.-Prof. Dr. Georg

III. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Starten Sie Ihre Suche...

III. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz